APx Acquisition Corp I

APx Acquisition Corp. I is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on May 13, 2021 and is headquartered in Mexico City, Mexico.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

APx Acquisition Corp. I is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on May 13, 2021 and is headquartered in Nashville, TN.

NASHVILLE, Tenn. , Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ:  APXI ) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice").

APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units

NASHVILLE, Tenn. , June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ:  APXI ) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").

APX Acquisition Corp. I Reports 10-K Delinquency Notice

NASHVILLE, Tenn. , March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company.

APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

NASHVILLE, Tenn., Dec. 28, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").

APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q

NASHVILLE, Tenn. , Dec. 1, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the "Business Combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and prevents disease ("Target"), that would result in a public listing of the combined company upon completion of the proposed Business Combination.

APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company

MEXICO CITY--(BUSINESS WIRE)--APx Acquisition Corp. I (NASDAQ: APXI) (“APx” or the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced that on August 23, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) advising the Company that the Company did not comply with NASDAQ's Listi

APx Acquisition Corp. I Receives NASDAQ Notification of Non-Compliance With Listing Rules

News for APx Acquisition Corp I Stock (APXI)